MMWR. Morbidity and mortality weekly report · 2022
Effectiveness of mRNA Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death - United States, March 2021-January 2022.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tenforde Mark W, Self Wesley H, Gaglani Manjusha, Ginde Adit A, Douin David J, Talbot H Keipp, Casey Jonathan D, Mohr Nicholas M, Zepeski Anne, McNeal Tresa, Ghamande Shekhar, Gibbs Kevin W, Files D Clark, Hager David N, Shehu Arber, Prekker Matthew E, Frosch Anne E, Gong Michelle N, Mohamed Amira, Johnson Nicholas J, Srinivasan Vasisht, Steingrub Jay S, Peltan Ithan D, Brown Samuel M, Martin Emily T, Monto Arnold S, Khan Akram, Hough Catherine L, Busse Laurence W, Duggal Abhijit, Wilson Jennifer G, Qadir Nida, Chang Steven Y, Mallow Christopher, Rivas Carolina, Babcock Hilary M, Kwon Jennie H, Exline Matthew C, Botros Mena, Lauring Adam S, Shapiro Nathan I, Halasa Natasha, Chappell James D, Grijalva Carlos G, Rice Todd W, Jones Ian D, Stubblefield William B, Baughman Adrienne, Womack Kelsey N, Rhoads Jillian P, Lindsell Christopher J, Hart Kimberly W, Zhu Yuwei, Adams Katherine, Surie Diya, McMorrow Meredith L, Patel Manish M, IVY Network
Аннотация
COVID-19 mRNA vaccines (BNT162b2 [Pfizer-BioNTech] and mRNA-1273 [Moderna]) are effective at preventing COVID-19-associated hospitalization (1-3). However, how well mRNA vaccines protect against the most severe outcomes of these hospitalizations, including invasive mechanical ventilation (IMV) or death is uncertain. Using a case-control design, mRNA vaccine effectiveness (VE) against COVID-19-associated IMV and in-hospital death was evaluated among adults aged ≥18 years hospitalized at 21 U.S. medical centers during March 11, 2021-January 24, 2022. During this period, the most commonly circulating variants of SARS-CoV-2, the virus that causes COVID-19, were B.1.1.7 (Alpha), B.1.617.2 (Delta), and B.1.1.529 (Omicron). Previous vaccination (2 or 3 versus 0 vaccine doses before illness onset) in prospectively enrolled COVID-19 case-patients who received IMV or died within 28 days of hospitalization was compared with that among hospitalized control patients without COVID-19. Among 1,440 COVID-19 case-patients who received IMV or died, 307 (21%) had received 2 or 3 vaccine doses before illness onset. Among 6,104 control-patients, 4,020 (66%) had received 2 or 3 vaccine doses. Among the 1,440 case-patients who received IMV or died, those who were vaccinated were older (median age = 69 years), more likely to be immunocompromised* (40%), and had more chronic medical conditions compared with unvaccinated case-patients (median age = 55 years; immunocompromised = 10%; p<0.001 for both). VE against IMV or in-hospital death was 90% (95% CI = 88%-91%) overall, including 88% (95% CI = 86%-90%) for 2 doses and 94% (95% CI = 91%-96%) for 3 doses, and 94% (95% CI = 88%-97%) for 3 doses during the Omicron-predominant period. COVID-19 mRNA vaccines are highly effective in preventing COVID-19-associated death and respiratory failure treated with IMV. CDC recommends that all persons eligible for vaccination get vaccinated and stay up to date with COVID-19 vaccination (4).